Join us for a discussion on the new data from TCT 2023 on transcatheter tricuspid valve replacement with the Columbia Structural Heart and Valve team. In this episode, delve into not only the latest findings but also the intriguing questions that arise from the groundbreaking research.

Dive into the latest developments at TCT 2023 as we dissect the low-risk randomized TAVR trials. In this episode, join the conversation with Columbia's Structural Heart and Valve team as they examine updates, share insights, and discuss how the evolving science may reshape our perspectives on TAVR.

Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX.

Welcome to Part 2 of our TVT 2023 Wrap-up, where we continue our exploration of The Structural Heart Summit's profound impact on treating structural heart disease. Join us as we review the transformative breakthroughs in transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies, ultimately shaping the landscape of patient care.

Explore the most important trials and presentations from TVT 2023 - The Structural Heart Summit. Held in Phoenix, AZ, from June 7th to 10th, TVT remains the most highly anticipated structural heart conference in the United States, focusing on transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies. Join our medical experts as they discuss groundbreaking advancements and research shaping the future of structural heart interventions.

Episode 14: Left Atrial Appendage Closure by Columbia University Valve Center

We review the available devices in clinical trials for TR and how we decide to enroll patients in certain trials versus others.

Secondary MR guidelines updates are discussed, while also discussing the role of clip vs TMVR for FMR patients, and how these affect clinical trials.

Episode 11: New Valve Guidelines 2020 Updates - Primary MR by Columbia University Valve Center

Dr. George and the Columbia Valve team discuss the new ACC/AHA guidelines for aortic stenosis, with a focus on the inclusion of age guidelines for the use of TAVR.